cTACE VS
DEB-TACE
cTACE uses Lipiodol oil to carry chemotherapy into tumour tissue. DEB-TACE uses microspheres that simultaneously load, deliver, and sustain drug release. Both produce similar overall survival β but they differ meaningfully in systemic toxicity, operator flexibility, and clinical response patterns.
analyticsAt a Glance
- check_circleDEB-TACE produces lower systemic doxorubicin exposure (lower Cmax) β fewer systemic adverse effects than cTACE
- check_circlecTACE offers greater operator flexibility β drug selection, emulsion concentration, and embolic material can be tailored per session
- check_circlePRECISION V RCT: DEB-TACE vs cTACE β similar overall survival; DEB-TACE showed significantly less liver toxicity and systemic adverse events
- check_circlecTACE remains the most widely used technique globally due to cost, familiarity, and equivalent survival outcomes
How cTACE and DEB-TACE Work: The Technical Difference
Both techniques use the same delivery route β superselective hepatic artery catheterisation β and both combine drug delivery with arterial embolisation. What differs is the mechanism of drug loading, delivery, and release kinetics.
βcTACE and DEB-TACE are two ways of achieving the same therapeutic goals. The Lipiodol approach gives operators more flexibility and costs less; the bead approach gives more predictable drug release kinetics and lower systemic toxicity. Neither is universally superior.β
cTACE: Lipiodol Emulsion + Embolic Material
Conventional TACE emulsifies chemotherapy β typically doxorubicin (50β75 mg), cisplatin, or mitomycin C β in Lipiodol (iodised poppy seed oil). This emulsion is injected into the tumour-feeding artery, where Lipiodol acts as a drug carrier and iodine contrast agent simultaneously. A separate embolic agent (gelfoam pledgets or spherical microspheres) is then injected to complete arterial occlusion. Drug release from the Lipiodol emulsion is relatively rapid.
DEB-TACE: Drug-Eluting Microspheres
Drug-eluting bead TACE uses microspheres (typically DC Bead, LifePearl, or HepaSphere) pre-loaded with doxorubicin. The beads are loaded by incubating them in a doxorubicin solution β drug loads electrostatically. When injected intra-arterially, the beads simultaneously embolise the vessel and sustain slow doxorubicin release over days to weeks. This controlled release reduces peak systemic drug concentrations (Cmax) and hepatic toxicity.
PRECISION V Trial: cTACE vs DEB-TACE β Key Results
The PRECISION V trial is the largest randomised controlled trial directly comparing cTACE and DEB-TACE in HCC patients. Its results are the primary evidence base for technique selection.
PRECISION V RCT β Tumour Response and Toxicity: DEB-TACE vs cTACE
Source: Lammer J et al., Cardiovasc Intervent Radiol. 2010;33(1):41β52. 212 patients. Primary endpoint: tumour response at 6 months.
- Objective tumour response: DEB-TACE52%
- Objective tumour response: cTACE44%
- Grade 3 liver toxicity: DEB-TACE20%
- Grade 3 liver toxicity: cTACE31%
- Grade 3 systemic adverse events: DEB-TACE25%
- Grade 3 systemic adverse events: cTACE37%
cTACE vs DEB-TACE: Comprehensive Head-to-Head Comparison
A structured comparison across the parameters most relevant to clinical technique selection.
| Parameter | cTACE (Conventional) | DEB-TACE (Drug-Eluting Beads) |
|---|---|---|
| Drug delivery vehicle | Lipiodol oil emulsion | Microspheres (DC Bead, LifePearl, HepaSphere, QuadraSphere) |
| Chemotherapy agents used | Doxorubicin, cisplatin, mitomycin C β operator choice | Doxorubicin (standard); irinotecan for DEBIRI-TACE (colorectal mets) |
| Drug release kinetics | Rapid β most drug released within hours to days | Sustained β controlled release over days to weeks; lower Cmax |
| Systemic drug exposure | Higher β more doxorubicin reaches systemic circulation | Lower β 50β70% reduction in systemic Cmax vs cTACE |
| Liver toxicity | More frequent β higher post-TACE ALT elevation | Less hepatotoxicity β PRECISION V showed significant reduction |
| Operator flexibility | High β drug type, concentration, volume, embolic material all customisable per session | Lower β bead size and drug load are pre-set; less real-time customisation |
| Post-embolisation syndrome | More pronounced β rapid drug release + embolisation | Slightly less severe β slower drug release may reduce inflammatory response |
| Imaging follow-up | Lipiodol is radiopaque β tumour shows dense uptake on CT (Lipiodol retention assessment) | No Lipiodol signal β MRI preferred for response assessment (mRECIST) |
| Tumour necrosis pattern | Broader embolisation β may affect peri-tumoral zone | More targeted β bead lodging in terminal arterioles; potentially more focal |
| Cost | Lower β Lipiodol and gelfoam are inexpensive | Higher β proprietary bead systems significantly more expensive per session |
| Availability | Universally available globally | Available at most well-equipped hepatology and IR centres; less accessible in low-resource settings |
| Overall survival equivalence | Yes β multiple meta-analyses show no significant OS difference | Yes β no OS advantage over cTACE in randomised data |
When to Prefer DEB-TACE vs cTACE: A Clinical Guide
In the absence of OS difference, technique selection is driven by patient-specific clinical factors and centre expertise.
Prefer DEB-TACE When:
The patient has borderline liver function (Child-Pugh B7) where reducing hepatotoxicity is a priority. Significant cardiac history where lower systemic doxorubicin Cmax reduces cardiotoxicity risk. Multiple TACE sessions are planned β cumulative systemic doxorubicin exposure is a concern with cTACE. Child-Pugh A patients with large or multifocal tumours where maximising drug delivery duration is advantageous.
Prefer cTACE When:
Cost is a significant factor β cTACE is substantially cheaper per session. The operator needs maximum flexibility to tailor drug selection (e.g. cisplatin or mitomycin C rather than doxorubicin). Lipiodol retention on CT is used as a response assessment tool. Superselective subsegmental TACE for small lesions where the difference in drug kinetics is less clinically significant. Centre has greater expertise and track record with cTACE.
Either Is Appropriate When:
Child-Pugh A, BCLC B HCC with good performance status where both techniques achieve equivalent outcomes. The patient and oncology team have no specific clinical reason to prefer one over the other. The decision is then determined by centre expertise, availability, and shared preference.
More from the TACE Resource Library
Continue exploring TACE β from patient selection to clinical evidence and access guides.
- What Is TACE? A Patient Introduction to Liver Cancer Embolisation
- TACE Patient Selection: BCLC Staging and Child-Pugh Score
- TACE Survival Data: Evidence from Pivotal Clinical Trials
- TACE as Bridge to Liver Transplant: How It Works
- TACE Therapy β Complete Treatment Guide
- Cryoablation for Liver Tumours: HCC and Metastases
Frequently Asked Questions
Common questions about the choice between cTACE and DEB-TACE.
Choosing Between TACE Techniques
My hospital uses cTACE but I've read DEB-TACE is better β should I insist on DEB-TACE?
Not necessarily. The PRECISION V and subsequent meta-analyses consistently show no difference in overall survival between cTACE and DEB-TACE β the choice does not meaningfully affect your long-term outcome if your liver function is adequate. DEB-TACE does have advantages in specific clinical situations (cardiac history, borderline liver function, planned multi-session programme), but for a typical Child-Pugh A patient with BCLC B HCC, the technique your hospital's interventional radiologist is most experienced with will produce the best results. Expertise and technique consistency matter more than technique choice when survival outcomes are equivalent. Discuss with your treating team whether your specific clinical situation warrants a preference.
How do I know if my TACE worked? Are CT and MRI different for cTACE vs DEB-TACE?
Yes β response assessment differs between techniques. After cTACE, Lipiodol appears as a dense white area on CT (radiopaque iodine retention), and response is assessed by measuring the non-enhancing necrotic zone on contrast-enhanced CT. After DEB-TACE, there is no Lipiodol signal β MRI with contrast (gadoxetate or standard gadolinium) using mRECIST criteria is the preferred assessment modality, measuring the arterially enhancing viable tumour within the treated zone. In both cases, the 4β6 week post-TACE imaging is the primary response assessment β a complete response means the entire treated tumour shows no arterial enhancement on contrast imaging.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About TACE Technique Selection?
CancerFax connects patients with specialist interventional radiologists in China and India who perform both cTACE and DEB-TACE β and can advise on which technique is most appropriate for your tumour characteristics, liver function, and systemic health.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.